Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

04:46 EDT 3rd May 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Lawsuitsettlementnews.com Secures Large Capital for Xarelto and Pradaxa Funding

NEW ORLEANS, Dec. 16, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that they have secured large capi...

Xarelto Lawsuits Now Exceed 3,000 in Number

NEW ORLEANS, Feb. 11, 2016 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reported today that the number of filed lawsuits against Bayer and Johnson & Johnson's subsidiary,...

Legal-Bay Lawsuit Settlement Funding Reports Xarelto News: Bellwether Trial Dates Announced

PHILADELPHIA, Nov. 16, 2015 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the first bellwether trial dates in the Xarelto multidistrict litigation have...

Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials

NEW ORLEANS, Jan. 18, 2016 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, reports today that Xarelto lawsuits have risen to...

Xarelto Lawsuits Rise as First Bellwether Cases Are Selected

NEW ORLEANS, Jan. 13, 2016 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the court has started the process of selecting 40 cases for the Xarelto multid...

EMA offers reassurance after Xarelto trial fault

Stroke-prevention drug Xarelto (rivaroxaban) can still be used safely even though a faulty device was…

Relief For Pradaxa: Praxbind Gets HTA Green Light

Pradaxa has so far not fared as well as the competition in global markets because it has a twice-daily dosing schedule and has higher rates of gastrointestinal intolerability, bleeding, and myocardial...

FDA Approves BI's Pradaxa for Prophylaxis of DVT, PE after Hip Replacement Surgery

​Boehringer Ingelheim Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) ...

Matching PubMed Articles

Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).

Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).

Pharmaceutical Approval Update.

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for ...

RECURRENT SUBRETINAL HEMORRHAGE ASSOCIATED WITH RIVAROXABAN ANTICOAGULATION.

To report a case of spontaneous recurrent significant subretinal hemorrhage in a patient on rivaroxaban (Xarelto).

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement